Wednesday, 10 June 2026 01:40 PM
Advertorial
As more adults compare online GLP-1 care options in 2026, this LIV Body GLP-1 review explores how the platform is positioned for provider-guided weight management support, what buyers should know about compounded semaglutide and tirzepatide, and which eligibility, pricing, pharmacy, and regulatory factors may influence the experience.
DES MOINES, IA / ACCESS Newswire / June 10, 2026 / Title Reference Notice: Promotional phrases in this headline, including "Clinician Prescribed" and "USA Made," reflect language published by LIV Body in its own marketing materials. This article uses those phrases for identification and consumer education. This publication does not independently verify, endorse, or guarantee those promotional phrases as performance, safety, quality, manufacturing, or clinical-outcome claims.
Advertorial Disclosure: This article is an advertorial and contains affiliate links. A commission may be earned on qualifying actions or purchases made through links in this content, at no additional cost to the reader. This content is promotional in nature but is written for consumer education. LIV Body is a telehealth platform connected to prescription medication services. LIV Body does not prescribe medication - prescribing decisions are made independently by licensed providers through OpenLoop Healthcare Partners, PC. Prescription medication is available only after consultation with and approval by a licensed healthcare provider, if clinically appropriate. Approval is not guaranteed. Compounded medications discussed in this article are not FDA-approved finished drug products and are not reviewed by FDA for safety, effectiveness, or quality before marketing. This article is not medical advice.
LIV Body GLP-1 2026 Research: Paige Hathaway's "Clinician Prescribed" Platform Examined - What It Costs, How the Three-Entity Program Works, and What to Verify Before You Enroll
View the current LIV Body GLP-1 offer (official LIV Body page)
TL;DR - What You Need to Know in 90 Seconds: LIV Body is a telehealth platform founded by fitness personality Paige Hathaway that connects people with OpenLoop Healthcare Partners, PC - an independent licensed medical group whose providers make all clinical prescribing decisions. If a provider determines you qualify (generally BMI 30 or higher, or BMI 27 or higher with a weight-related condition), you may receive a prescription for compounded semaglutide or compounded tirzepatide, if medically appropriate. LIV Body's published materials list four pharmacy providers involved in fulfillment: RedRock Pharmacy, Health Warehouse, Precision Compounding Pharmacy, and Triad Rx. Patients should verify the dispensing pharmacy, medication label, and instructions before use. The medications are compounded, meaning they are prepared by compounding pharmacies rather than sold as FDA-approved finished brand-name drug products. Compounded versions may be prepared using the same active pharmaceutical ingredient as certain FDA-approved GLP-1 medications, but they are not the same finished products and are not FDA-approved. In a March 3, 2026 press announcement (FDA.gov press announcement, March 3, 2026), the FDA issued warning letters to 30 telehealth companies specifically for making claims that implied sameness with FDA-approved products - a category-wide compliance signal every buyer should understand. LIV Body's brand-stated starting prices are $179/month for compounded semaglutide and $279/month for compounded tirzepatide - confirm your exact checkout price before enrollment. Approval is not guaranteed. Regulatory context every buyer needs in June 2026: On April 30, 2026, the FDA proposed removing semaglutide and tirzepatide from the 503B outsourcing bulks list - the pathway that enabled large-scale compounding. A public comment period is open through June 29, 2026. The 503A patient-specific compounding pathway - under which individual prescriptions are filled by state-licensed pharmacies - operates under a separate legal framework and currently remains intact. Verify the current compounding status of LIV Body's named pharmacy providers directly with the platform before enrolling. This article explains the program structure, the clinical evidence behind GLP-1 medications as a class, and what to verify before you decide.
This article is not medical advice. LIV Body's GLP-1 program involves prescription medication services. Prescription medication is available only if a licensed healthcare provider determines it is clinically appropriate after review. Approval is not guaranteed. People who are pregnant, planning pregnancy, have certain endocrine cancer histories, have a history of pancreatitis, have gallbladder concerns, take interacting medications, or have other relevant medical conditions should discuss risks and alternatives with a qualified healthcare professional before considering any GLP-1 medication program.
View the current LIV Body GLP-1 offer (official LIV Body page)
LIV Body GLP-1 2026 Quick Verification Snapshot - As of June 2026
Platform Name: LIV Body, per brand materials (operated by LivBody HoldCo LLC)
Clinical Partner: OpenLoop Healthcare Partners, PC, per LIV Body/OpenLoop published materials (and state-specific affiliated entities)
Medication Types Discussed: Compounded semaglutide and compounded tirzepatide, if prescribed by a licensed provider based on individual medical evaluation
Starting Price: Brand-stated pricing includes semaglutide from $179/month, tirzepatide from $279/month, and a program FAQ stating the LIV Body GLP-1 program starts at $249/month. Confirm the exact checkout price before enrollment.
Delivery: LIV Body states approved medication is shipped to the patient's door in discreet, temperature-controlled packaging. Confirm current shipping terms before enrollment.
Pharmacy Providers Listed by Brand: RedRock Pharmacy (St. George, UT), Health Warehouse (Florence, KY), Precision Compounding Pharmacy (Bellmore, NY), Triad Rx (Daphne, AL). This publication has not independently audited current licensing, operations, fulfillment, or dispensing practices.
States Served: Per brand, all 50 states plus Washington, D.C. Subject to change. Verify availability in your state before enrolling.
Founder: Paige Hathaway - fitness personality and brand figure; not a prescribing provider
Contact: [email protected] | (260)833-7235 | 317 6th Avenue, Suite 400, Des Moines, Iowa 50309
USA Made claim: Per brand materials, compounded medications are prepared by pharmacy providers with US addresses. This publication has not independently audited those pharmacies' manufacturing practices.
FDA Status: Compounded medications are not FDA-approved finished drug products and are not reviewed by FDA for safety, effectiveness, or quality before marketing. Per a March 3, 2026 FDA press announcement (FDA.gov press announcement, March 3, 2026), the agency issued warning letters to 30 telehealth companies for making claims that implied sameness with FDA-approved products. Buyers should understand this distinction clearly before enrolling in any compounded GLP-1 program.
Clinical Approval: Not guaranteed. Prescribing decisions are made by licensed providers through OpenLoop Healthcare Partners, PC based on independent medical evaluation.
Subscription: Monthly recurring billing. Cancellation available via [email protected] or through your provider. Read current terms before submitting payment.
Refund policy: Per Terms of Use, fees for healthcare services are generally non-refundable. Verify directly at livbody.com before enrolling.
Freshness: As of June 2026. Verify current pricing, availability, and program terms on the official LIV Body website before any enrollment decision.
About the Promotional Language in This Article's Title
If you arrived here from a LIV Body advertisement, you've already seen the brand's marketing language - phrases like "Clinician Prescribed," "USA Made," "Work with your biology, not against it," "Food Noise," and "Stop Fighting Your Biology." Those phrases are LIV Body's own. This article uses them in the title because you came from brand advertising and continuity matters when you're making a health decision - you should be reading about the exact program you saw advertised.
Here's what those phrases actually mean, broken down one by one:
"Clinician Prescribed": Source - LIV Body's official lander. What it means - a licensed healthcare provider employed by or contracted with OpenLoop Healthcare Partners, PC (an independent medical group) reviews your intake and, if you qualify medically, may write a prescription. What it doesn't mean - LIV Body itself doesn't prescribe anything. The platform is a technology company that connects patients to independent clinicians. Whether you receive a prescription depends on the licensed provider's independent clinical judgment, not the platform's decision. Approval is not guaranteed.
"USA Made": Source - LIV Body's official lander. What it means - according to the brand's published materials, compounded medications are prepared by pharmacy providers with US addresses listed in those materials. What it doesn't mean - this publication has not independently audited the manufacturing practices, current licensing, or fulfillment operations of those pharmacies. The compounded medications are not FDA-approved finished drug products regardless of where they are compounded.
"Food Noise": Source - LIV Body's lander and category marketing language. "Food Noise" is not a formal medical term. LIV Body uses the phrase to describe persistent food-related thoughts, cravings, or appetite signals that some people experience while trying to manage weight. GLP-1 medications may affect appetite and satiety pathways in some patients, but individual response varies. For any specific patient, no reduction in food-related thoughts is guaranteed.
"Doctor-led plans": Source - LIV Body lander. What it means - licensed medical providers through OpenLoop Healthcare Partners, PC create treatment plans if you're approved. Approval is not guaranteed, and the specific credentials of your assigned provider (MD, NP, PA) may vary. The telehealth consent form from OpenLoop Healthcare Partners, PC discloses that providers may be nurse practitioners or physician assistants.
Buyer Takeaway: Every phrase in this title comes directly from LIV Body's own advertising. They describe real features of the program as the brand positions it, but each one has a specific and limited meaning. This article's job is to give you the translation - so your enrollment decision is based on facts, not impressions.
LIV Body GLP-1 2026 Fast Facts: What Every Buyer Should Know in 30 Seconds
LIV Body: telehealth platform, not a medical practice - connects patients to OpenLoop Healthcare Partners, PC
OpenLoop Healthcare Partners, PC: the independent licensed medical group whose providers make all prescribing decisions
Compounded semaglutide: may be prepared using the same active ingredient as Wegovy® and Ozempic® - not the same finished product; not FDA-approved
Compounded tirzepatide: may be prepared using the same active ingredient as Zepbound® and Mounjaro® - not the same finished product; not FDA-approved
Semaglutide starting price: $179/month per brand; program listed as starting at $249/month on lander FAQ - confirm at checkout
Tirzepatide starting price: $279/month per brand - confirm at checkout
Approval: not guaranteed - requires licensed provider review and independent clinical eligibility determination
Typical GLP-1 eligibility criteria: BMI 30 or higher, or BMI 27 or higher with a qualifying weight-related condition (per standard GLP-1 prescribing guidelines; individual provider determination applies)
Delivery method: weekly self-injection per brand lander - verify with your provider
Shipping: LIV Body states free overnight, discreet, temperature-controlled packaging - confirm current terms before enrollment
Pharmacy providers listed by brand: RedRock (UT), Health Warehouse (KY), Precision Compounding (NY), Triad Rx (AL) - this publication has not independently audited current operations
Billing: monthly subscription - cancellation available at any time; read current terms before submitting payment
LIV Body supplementary program: includes "Muscle Guard" nutritional strategy (brand-positioned) and optional Care Coach support
Paige Hathaway: fitness personality and brand founder; program framing is active-lifestyle-centered - not a prescribing provider
503B outsourcing compounding (large-scale): FDA proposed removal of semaglutide and tirzepatide from 503B bulks list on April 30, 2026; public comment period closes June 29, 2026 - large-scale 503B compounding pathway under active regulatory review
503A patient-specific compounding: operates under a separate legal framework independent of shortage-list status; currently intact; requires a valid patient-specific prescription and licensed prescriber documentation
LIV Body's named pharmacy providers: RedRock Pharmacy, Health Warehouse, Precision Compounding Pharmacy, Triad Rx - ask the platform and your provider which compounding pathway each uses and confirm current operational status before your first fill
Verify before enrolling: the compounded GLP-1 regulatory framework is under active review as of June 2026; confirm current program availability and pharmacy status directly with LIV Body before submitting payment
Not for: anyone without clinical eligibility, anyone seeking FDA-approved finished products, anyone in a medical emergency
Not covered: insurance not accepted; HSA/FSA may be applicable - verify with your plan administrator
What Is LIV Body's GLP-1 Program - and What Separates It from Other Telehealth Platforms
You've probably noticed that the telehealth GLP-1 market has gotten crowded fast. Platforms offering compounded semaglutide and tirzepatide have proliferated since 2023, and the category looks almost identical from the outside - fill out a form, see a provider, receive medication if approved. That surface-level similarity is exactly why it's worth slowing down and understanding what actually differentiates one platform from another before you hand over your payment information and health data.
LIV Body's positioning is built around one core idea: that the people who need GLP-1 support most are people who've already been doing the work - eating well, exercising, staying active - and still hitting a metabolic wall that hard work alone can't break. The fitness-community framing associated with Paige Hathaway - LIV Body's founder and public brand figure - describes watching dedicated people grind without results. The brand frames the reality that hormonal and physiological factors can work against weight management even in highly motivated, active people. Clinical decisions are handled separately by licensed providers through OpenLoop Healthcare Partners, PC.
That positioning shapes the program design. LIV Body describes "Muscle Guard" as a nutritional strategy designed to support lean-mass maintenance during weight loss. This publication has not independently verified body-composition outcomes from the protocol - patients should discuss protein intake, resistance training, and lean-mass preservation with their licensed provider. The program also includes dedicated Care Coach support. LIV Body states that its Care Coach program may help patients manage side effects and may support better program adherence. The brand references a "lose up to 6% more weight" figure in connection with Care Coach enrollment - this publication has not independently verified the methodology, sample size, or comparison group behind that figure. Individual results vary and coaching should not be treated as a guarantee of additional weight loss.
What LIV Body doesn't do is prescribe. That distinction matters enormously - both for your safety and for understanding what you're actually signing up for. The platform connects you to OpenLoop Healthcare Partners, PC, the independent licensed medical group that makes all clinical decisions. LIV Body is a technology company. The prescribing is done by licensed providers who are independent of the platform, and whose judgment cannot be directed by the business.
Buyer Takeaway: LIV Body is a fitness-community-rooted telehealth platform built for people who want GLP-1 medication support - if prescribed - layered alongside an active lifestyle. It's built for a specific type of buyer. Whether it fits your situation starts with the 3-minute intake form - but understanding the structure first helps you ask better questions when you get there.
The Three Entities Behind the LIV Body Program: What You're Actually Enrolling In
This is the most important section in the article from a consumer protection standpoint. The LIV Body GLP-1 program involves three distinct organizations. Understanding who does what protects you as a patient and helps you ask the right questions before you enroll.
Entity 1: LIV Body (LivBody HoldCo LLC)
LIV Body is the platform. Per its published Terms of Use, LIV Body does not provide any medical services. It does not prescribe medication. It does not operate as a pharmacy. It does not control or interfere with the independent clinical judgment of licensed providers. LIV Body's role is to connect you to the licensed clinical infrastructure - to provide the intake technology, facilitate the telehealth experience, and coordinate the logistics of your care. When you sign up on go.livbody.com, you're enrolling in LIV Body's platform. You're not entering into a patient-provider relationship with LIV Body itself. LIV Body is not responsible for clinical outcomes, and its liability is explicitly limited in its published Terms of Use.
Entity 2: OpenLoop Healthcare Partners, PC
OpenLoop Healthcare Partners, PC is the independent licensed medical group whose licensed providers review your intake and make all clinical prescribing decisions. The telehealth consent form you'll sign is OpenLoop Healthcare Partners, PC's consent form - not LIV Body's. OpenLoop providers include physicians, nurse practitioners, and physician assistants licensed in the state where you're located. They review your health profile, determine whether GLP-1 medication is clinically appropriate for you, and - if it is - write the prescription. If they determine you don't qualify, you won't receive medication. That determination is theirs alone, and LIV Body cannot override it. OpenLoop Healthcare Partners, PC has state-specific affiliated entities (OpenLoop Healthcare Partners California, PC; OpenLoop Healthcare Partners Colorado, PC; OpenLoop Healthcare Partners New Jersey Professional Corporation; OpenLoop Healthcare Partners, Wisconsin, S.C.) operating where state law requires a separate entity. Your provider is employed by or contracted with one of these entities based on your location.
Entity 3: The Pharmacy Providers
If your provider prescribes GLP-1 medication, the prescription goes to one of the pharmacy providers listed in LIV Body's published materials: RedRock Pharmacy (1240 E 100 S #220, St. George, UT 84790), Health Warehouse (7107 Industrial Rd., Florence, KY 41042), Precision Compounding Pharmacy (2657 Merrick Road, Bellmore, NY 11710), and Triad Rx (26258 Pollard Road, Daphne, AL 36526). This publication has not independently audited current licensing, fulfillment, pharmacy operations, or quality practices at these locations. Patients should confirm the dispensing pharmacy and verify the medication label, dosing instructions, and storage requirements before use. LIV Body states it doesn't produce compounded medications and that you may receive medication that looks different from what's shown on the brand's website.
Why this structure matters to you: You're not buying medication from LIV Body. You're accessing a clinical service through a licensed medical group that uses a technology platform. The prescription, if any, is a medical act performed by a licensed independent provider. The medication, if any, is prepared by a licensed pharmacy. LIV Body is the connection infrastructure. Understanding those three layers prevents the most common misunderstanding about telehealth GLP-1 programs - the assumption that the company you pay is the company that prescribes.
Buyer Takeaway: You're enrolling in a three-entity structure consistent with common telehealth prescription-program architecture: platform, clinical provider group, and pharmacy provider. LIV Body doesn't prescribe. Approval is not guaranteed. Your provider's independent clinical judgment governs the outcome.
View the LIV Body GLP-1 program - see current offer and eligibility details (official LIV Body page)
How to Read LIV Body's Marketing Language
LIV Body runs active advertising. If you came here from a social media ad, a paid search result, or content connected to the fitness-community framing associated with Paige Hathaway, you've been exposed to a specific set of phrases the brand uses consistently. This section translates each one so you're not making a significant health and financial decision based on marketing copy alone.
The brand's headline on its lander is: "Work with your biology, not against it." This describes how GLP-1 medications are positioned - working with physiological mechanisms that regulate appetite and metabolic rate, rather than relying solely on willpower and caloric restriction. It's a framing of the mechanism the brand is describing, not a performance guarantee. Whether your biology responds to GLP-1 medication, and to what degree, is determined by your provider's evaluation and your individual clinical response.
The phrase "Stop Fighting Your Biology" carries the same meaning. It addresses the reality that weight regulation involves hormonal and genetic factors that don't respond to effort alone. The brand's statement that "nearly 70% of weight is genetically determined" appears on a secondary LIV Body site page - this is a figure that circulates in obesity medicine literature, but you should verify it against current research before using it as a personal clinical premise. This publication does not independently endorse that specific statistic.
The phrase "Food Noise" is not a formal medical term. LIV Body uses it to describe persistent food-related thoughts, cravings, or appetite signals that some people experience while trying to manage weight. GLP-1 medications may affect appetite and satiety pathways in some patients, and some clinical literature describes reductions in appetite-related preoccupation on GLP-1 therapy. Individual response varies. No reduction in food-related thoughts is guaranteed for any individual patient. "Food Noise" is a brand descriptor for a real phenomenon that some patients report - but it isn't a clinical guarantee for any program.
The phrase "Clinician Prescribed" means a licensed provider reviews your intake and, if you qualify, writes a prescription based on independent clinical judgment. It doesn't mean prescriptions are automatic. The telehealth consent form from OpenLoop Healthcare Partners, PC explicitly states: "I understand that participating in a telehealth visit is not a guarantee that I will be given a prescription." That language is in the consent you'll sign. Read it before you pay.
"Doctor-led plans" on the lander means your treatment plan is created by a licensed medical provider through OpenLoop. The provider may be a physician, nurse practitioner, or physician assistant. The consent form discloses that in some cases the provider may be a nurse practitioner or physician assistant rather than a physician. That's standard telehealth practice - but it's worth knowing before you assume "doctor-led" means MD exclusively.
"No hidden fees. Medication, clinicians, and shipping included" is LIV Body's stated value positioning. This is a brand comparison claim. This publication has not independently audited whether all program costs are reflected in the published price or whether additional fees might apply in your specific situation. Verify current pricing, inclusions, and cancellation terms at checkout before submitting payment.
Buyer Takeaway: LIV Body's marketing language describes the category in ways that align with how GLP-1 programs generally work. But each phrase has a defined and limited scope. This section has translated the major phrases so your decision is based on what the program is, not what the advertising implies.
What Compounded Semaglutide and Tirzepatide Actually Are - and What They're Not
This is the section most telehealth GLP-1 articles skip or bury in fine print. You shouldn't skip it - it's the most important regulatory distinction in the entire category, and it became significantly more relevant following FDA enforcement action in early 2026.
Semaglutide is the active pharmaceutical ingredient in Wegovy® (FDA-approved for chronic weight management) and Ozempic® (FDA-approved for type 2 diabetes). Tirzepatide is the active ingredient in Zepbound® (FDA-approved for chronic weight management) and Mounjaro® (FDA-approved for type 2 diabetes). These are FDA-approved finished drug products manufactured by Novo Nordisk and Eli Lilly respectively - products that went through the FDA's full pre-market approval process for safety, effectiveness, and quality.
Compounded semaglutide and compounded tirzepatide are different products. They may be prepared using the same active pharmaceutical ingredients, but they are not FDA-approved finished drug products. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. That's not a technicality - it's a meaningful regulatory distinction that every patient in this category should understand before starting treatment.
In a press announcement published March 3, 2026 (FDA.gov press announcement, March 3, 2026), the FDA issued warning letters to 30 telehealth companies for making claims that implied sameness with FDA-approved products - specifically calling out companies that advertised drug products in ways that obscured the compounded nature of the product. FDA Commissioner Marty Makary stated directly: "Compounded drugs can be important for overcoming shortages or meeting unique patient needs - but compounders should not try to compound drugs in a way that circumvents FDA's approval process." That enforcement action is category context you deserve to have before you enroll anywhere.
Important compounded-medication context: Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products. FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. The FDA has also raised concerns involving compounded GLP-1 products, including dosing errors, improper storage during shipping, fraudulent products, adverse event reports, and the use of semaglutide salt forms that the FDA has stated should not be used for compounding. Patients should only use prescription medication under licensed-provider supervision and should verify the dispensing pharmacy, medication label, dosing instructions, storage requirements, and administration instructions before use.
LIV Body's own lander and telehealth consent form are transparent about this. The lander states: "Compounded GLP-1s are produced in FDA-regulated facilities. Although these facilities are highly regulated, the medications are not FDA-approved or evaluated for safety, efficacy, or quality." The OpenLoop telehealth consent form you sign states the same. This is accurate, and it's information you should carry into every conversation with your provider.
Compounding pharmacies operate under state pharmaceutical regulation and, for facilities meeting certain thresholds, under FDA oversight of the facility itself (503A and 503B designations). The oversight is real. But the specific compounded product you receive has not gone through the same pre-market review that Wegovy® or Zepbound® underwent. That's the relevant distinction for your decision.
LIV Body's published materials list four pharmacy providers. This publication has not independently audited current licensing, fulfillment, or quality practices at those locations. Patients should confirm the dispensing pharmacy and verify the medication label, dosing instructions, and storage requirements directly before use.
Buyer Takeaway: Compounded GLP-1 medications may be prepared using the same active pharmaceutical ingredients as name-brand versions, but they are not the same finished products and are not FDA-approved. The FDA issued warning letters in March 2026 (sourced: FDA.gov press announcement, March 3, 2026) targeting companies that obscured this distinction. Understanding it protects you.
The Compounded GLP-1 Regulatory Window in June 2026: What Every Buyer Should Understand Before Enrolling
If you're reading this in June 2026 and seriously considering any compounded GLP-1 program - including LIV Body's - there is genuine regulatory context you deserve to have before you make a decision. This isn't manufactured urgency. It's a specific and verifiable set of facts that directly affects the category you're evaluating.
What happened: the timeline from shortage to enforcement
Compounded semaglutide and compounded tirzepatide became widely available starting in 2022 because both drugs appeared on the FDA's official drug shortage list. That designation gave compounding pharmacies - particularly 503B outsourcing facilities - the legal pathway to produce and distribute them at scale. At peak, compounded GLP-1 medications accounted for roughly 30% of US supply, according to published industry estimates, at prices of $150 to $300 per month versus $1,000-plus for brand-name versions.
The FDA declared the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved on February 21, 2025. Both decisions came after the manufacturers confirmed supply capacity could meet national demand. When a shortage ends, the legal basis for most compounding activity ends with it. The FDA gave pharmacies wind-down periods - 60 days for 503A state-licensed pharmacies, 90 days for 503B outsourcing facilities. Those deadlines passed in 2025.
Where things stand right now: two separate legal pathways
Understanding the difference between 503A and 503B compounding is the most practically important thing a buyer can know in June 2026.
503B outsourcing facilities are FDA-registered, large-scale compounding operations. They were the primary supply source during the shortage era. With neither semaglutide nor tirzepatide currently on the FDA drug shortage list or the 503B bulks list, these facilities face serious legal constraints on producing these medications. On April 30, 2026, the FDA formally proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list entirely - the regulatory mechanism that governs which active pharmaceutical ingredients outsourcing facilities may use. The public comment period runs through June 29, 2026. If finalized, this closes the 503B compounding pathway for these medications with no remaining legal route. The Federal Register docket number for this proposal is 2026-08552.
503A patient-specific compounding operates under a different and currently intact legal framework. Section 503A of the Federal Food, Drug, and Cosmetic Act covers state-licensed pharmacies that compound medications for individual patients based on valid, patient-specific prescriptions. This pathway does not depend on shortage-list status in the same way. However, 503A pharmacies must comply with the "essentially a copy" standard - meaning the compound must offer a documented clinical difference from the commercially available version for that specific patient. On April 1, 2026, the FDA reiterated its enforcement policy: it does not currently intend to take action where a 503A compounder fills four or fewer prescriptions per calendar month of a drug that is "essentially a copy." That safe harbor is narrow, and it signals the FDA's direction.
What this means for LIV Body buyers specifically
LIV Body's published materials list four pharmacy providers: RedRock Pharmacy, Health Warehouse, Precision Compounding Pharmacy, and Triad Rx. This publication has not independently confirmed which compounding pathway each of these pharmacies currently uses, whether each has received any FDA correspondence, or what their current operational status is as of June 2026.
Before enrolling in LIV Body's program - or any compounded GLP-1 program - these are the specific questions to ask the platform and your assigned provider:
Which compounding pathway (503A or 503B) does your dispensing pharmacy currently use?
Has the dispensing pharmacy received any FDA warning letters, inspection notices, or enforcement correspondence?
Has the platform confirmed the current legal and operational status of its pharmacy network in light of the April 30, 2026 FDA proposal?
If the 503B proposal is finalized, what is the platform's plan for continuing to fulfill prescriptions?
What documentation is your provider maintaining to satisfy the 503A "significant difference" or individualized clinical need standard?
None of these questions are reasons to avoid the category. They're the questions an informed buyer asks before committing to a monthly subscription program in a category under active regulatory review. Platforms that answer them clearly and specifically are operating transparently. Platforms that can't or won't are a different matter.
What this is not
This is not a reason to rush into enrolling before a deadline. That would be manufactured urgency, and this article doesn't do that. The 503A pathway is intact and has no announced end date. Individual patient-specific compounding by licensed state pharmacies is a well-established practice that predates the GLP-1 shortage era entirely. What is changing is the scale and accessibility of the category - not a total shutdown.
It's also worth noting that brand-name alternatives are now more accessible than they were in 2023 or 2024. Oral Wegovy received FDA approval in late 2025. LillyDirect offers Zepbound directly at $299-$449 per month. A Medicare GLP-1 Bridge program covering Wegovy and Zepbound at a $50/month Part D copay is reported as beginning July 2026. For buyers who want FDA-approved finished products rather than compounded alternatives, those options exist.
Buyer Takeaway: The compounded GLP-1 access window that existed from 2022 through 2025 has structurally changed. The 503A patient-specific pathway remains intact, but the large-scale 503B pathway is under active regulatory action. Before enrolling in LIV Body or any compounded GLP-1 program, ask the platform directly which compounding pathway your pharmacy uses, what its current legal status is, and how it's positioned for the regulatory environment ahead. That's not a reason to avoid the program - it's the right question to ask before any significant health and financial commitment.
Does the GLP-1 Mechanism Actually Work? What Clinical Evidence Shows
GLP-1 receptor agonists are among the most extensively studied weight management medications in recent pharmaceutical history. The clinical evidence base is substantial, and understanding it helps you contextualize what to reasonably expect - while keeping in mind that trial results reflect brand-name medications in controlled settings, not real-world outcomes from any specific compounded program.
The STEP-1 trial - a landmark randomized controlled trial published in the New England Journal of Medicine - studied semaglutide 2.4 mg administered weekly in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition, over 68 weeks. Participants following semaglutide alongside a reduced-calorie diet and exercise program lost an average of approximately 14.9% of body weight, compared to approximately 2.4% in the placebo group. These results reflect FDA-approved brand-name semaglutide studied in controlled clinical trial settings - not LIV Body's specific compounded preparations or any guaranteed real-world patient outcome.
The SURMOUNT-1 trial, published in the New England Journal of Medicine, studied tirzepatide - the dual GLP-1 and GIP agonist - in adults with obesity or overweight with at least one weight-related condition over 72 weeks. Participants achieved average weight loss of approximately 20.9% of body weight at the highest dose (15 mg weekly). These results also reflect FDA-approved brand-name tirzepatide in controlled conditions, not compounded tirzepatide outcomes in a real-world program. Individual results vary significantly.
GLP-1 medications have a substantial clinical evidence base for eligible patients when prescribed and monitored by qualified healthcare professionals. Clinical trial protocols and obesity-medicine guidance generally evaluate GLP-1 medications alongside nutrition, physical activity, and ongoing medical supervision rather than as standalone interventions. LIV Body's active lifestyle positioning aligns with this framework; the program is designed to pair potential medication use with fitness and nutritional support, not replace those elements.
Here's a realistic clinical picture: semaglutide and tirzepatide have substantial clinical evidence as prescription weight-management tools for eligible patients when prescribed and monitored by qualified healthcare professionals. Multi-year, large-scale, randomized controlled trials are the foundation of that evidence - which puts them in a meaningfully different category from supplements with limited research behind them. That same clinical evidence base also shows that these medications don't work equally for every patient, that gastrointestinal side effects are common especially during dose escalation, and that weight tends to return when medication is discontinued without sustained lifestyle changes. The evidence is strong; it isn't a promise of any individual outcome.
Buyer Takeaway: GLP-1 medications have a substantial clinical evidence base. Published trial data reflects brand-name medications in controlled conditions - not proof of compounded-product outcomes from any specific telehealth program. Individual results vary. LIV Body's program is designed to pair potential medication use with lifestyle support, which aligns with how GLP-1 therapy is most effectively used clinically.
The LIV Body Enrollment Process - Step by Step, With What to Expect
LIV Body's lander describes a three-step process. Here's what each step involves based on publicly available information from the brand.
Step 1 - Complete the Intake Form (approximately 3 minutes)
You'll answer questions on LIV Body's secure intake form covering your health profile, weight history, current medications, and relevant medical conditions. The brand describes this as a qualification screening. The OpenLoop telehealth consent form you sign during this process states that the assessment "does not create a doctor-patient relationship between the individual completing the assessment and LIV Body." If you're screened out at this stage, per the brand's stated process, your information won't be submitted to a provider and you'll need to seek care another way.
Step 2 - Clinician Review
A licensed provider employed by or contracted with OpenLoop Healthcare Partners, PC reviews your intake. Per the brand's FAQ, this includes a review of your profile to ensure GLP-1s are "safe and right for you." The provider makes the independent clinical decision about whether to prescribe, at what dose, and with what monitoring plan. This is where "Clinician Prescribed" actually happens - or doesn't. Approval is not guaranteed.
Step 3 - Delivery, If Approved
If prescribed, your medication ships from one of the listed pharmacy providers to your door. The brand states overnight delivery in discreet, temperature-controlled, unmarked packaging with free expedited shipping included - confirm current shipping terms before enrollment. Before use, verify the dispensing pharmacy, medication label, dosing instructions, and storage requirements.
Ongoing care
After enrollment, the program includes provider access, a dedicated Care Coach (per brand positioning), access to LIV Body's supplement deals, and the "Muscle Guard" nutritional strategy. LIV Body states its Care Coach program may help patients manage side effects and may support better program adherence - a brand-stated benefit; individual results vary.
Buyer Takeaway: The enrollment process is designed to be fast. But the clinical review step is the one that matters most and can't be accelerated. Your provider's decision is independent and based on your individual health profile.
Start the LIV Body GLP-1 assessment (official LIV Body page)
LIV Body GLP-1 Pricing - What You'll Pay and What's Included
LIV Body's published materials contain multiple price references. The lander lists compounded semaglutide starting at $179/month and compounded tirzepatide starting at $279/month. The FAQ also states that the LIV Body GLP-1 program starts at $249/month. Because medication type, dosage, program terms, subscription structure, and checkout pricing may vary, you should verify the exact current price, renewal terms, cancellation terms, and included services before submitting payment.
The brand positions its pricing against what it calls "Standard Clinics" and describes the program as including medication, clinicians, and shipping - this is a brand-stated positioning claim. This publication has not independently audited whether all program costs are reflected in the published starting prices or whether additional fees might apply in your specific situation. Verify current pricing, inclusions, and any additional fees directly at go.livbody.com before enrolling. Prices are subject to change per the Terms of Use.
For context on category pricing: brand-name Wegovy® carries a list price of approximately $1,349 to $1,850 per month without insurance. Compounded alternatives across telehealth platforms generally range from $179 to $399 per month depending on the medication and dose. LIV Body's brand-stated pricing is consistent with the competitive range for compounded GLP-1 telehealth programs as of mid-2026. Comparison references against brand-name medication prices are the brand's stated reference points and may not reflect your individual insurance situation or prevailing market prices.
Insurance is not accepted per the brand's positioning. HSA and FSA funds may be applicable - verify with your plan administrator. The program is billed as a monthly subscription with payments charged automatically at the billing cycle. You can cancel at any time by emailing [email protected] or contacting your provider directly. Fees paid are generally non-refundable per the Terms of Use. Readers should review the current checkout flow, renewal terms, cancellation method, and refund policy before submitting payment. State-specific automatic-renewal rules may apply.
Buyer Takeaway: LIV Body's brand-stated pricing is competitive within the compounded telehealth GLP-1 category. Confirm the exact all-in cost at checkout before billing, understand the subscription structure, and save the cancellation email address before your first payment.
What Can Buyers Verify About LIV Body GLP-1 Before Enrolling?
Buyers can verify several published program details before enrollment. LIV Body identifies itself as the platform (LivBody HoldCo LLC, 317 6th Avenue, Suite 400, Des Moines, Iowa 50309). OpenLoop Healthcare Partners, PC is identified in the telehealth consent materials as the clinical provider group. LIV Body's published materials list multiple pharmacy providers involved in fulfillment. The brand also publishes contact information, pricing references, and disclosures explaining that compounded GLP-1 medications are not FDA-approved finished drug products. The three-entity structure LIV Body uses is consistent with common telehealth prescription-program architecture: platform, clinical provider group, and pharmacy provider.
This article does not independently audit medical licensure, pharmacy operations, fulfillment practices, patient outcomes, or legal compliance. Readers should verify current terms, clinical eligibility, medication details, and provider guidance before enrolling.
On the clinical side, GLP-1 medications have a substantial clinical evidence base for eligible patients when prescribed and monitored by qualified healthcare professionals. The specific compounded preparations haven't undergone individual clinical trials, but they may be prepared using the same active pharmaceutical ingredients as extensively studied brand-name medications. They are not the same finished products, and individual results in a real-world telehealth program will vary based on adherence, dose, lifestyle factors, provider guidance, and individual physiology.
What third-party consumer feedback platforms show about LIV Body reflects highly variable individual experiences. The brand's lander features brand-reported testimonials describing positive experiences - these are individual accounts, not typical results. Per FTC guidelines, customer ratings and testimonials are brand-reported and have not been independently audited. Individual experiences vary.
Buyer Takeaway: LIV Body's platform structure is verifiable from publicly available materials. GLP-1 medications have a substantial clinical evidence base as a class. Whether this specific program is right for you requires a conversation with a licensed provider - which is exactly what the intake process is designed to initiate. Start with the assessment, but go in informed.
Start the LIV Body GLP-1 eligibility assessment (official LIV Body page)
LIV Body vs. Other Telehealth GLP-1 Platforms - What's Different
The category has grown fast. Platforms offering compounded semaglutide and tirzepatide through telehealth now number in the dozens. From a structural standpoint, most share the same basic architecture: a technology platform, a licensed clinical partner, and a network of compounding pharmacies. The clinical infrastructure is largely standardized because the regulatory requirements are the same for everyone.
What differentiates platforms in this category tends to come down to a few things: positioning and community, pricing and plan structure, support infrastructure, and supplementary program elements.
LIV Body's differentiator is its fitness community origin and the active lifestyle framing associated with founder Paige Hathaway. The program is designed by and for people who are already physically active and want to address the metabolic component of their weight management alongside their fitness work. The "Muscle Guard" strategy, the Care Coach program, and the supplement line integration are all expressions of this brand positioning. Clinical decisions are handled separately by licensed providers through OpenLoop Healthcare Partners, PC - the fitness-community positioning shapes the support experience, not the clinical evaluation.
Other platforms compete primarily on price, speed, or breadth of medication options. LIV Body's brand-stated pricing ($179-$279/month depending on medication - confirm at checkout) is competitive but not necessarily the lowest in the category. The brand's positioning is that it delivers added value through coaching, supplement access, and active lifestyle integration - whether that matches your needs depends on your situation.
The most important thing to compare across platforms is the licensed medical group and its clinical approach. OpenLoop Healthcare Partners, PC appears across multiple telehealth platforms as a clinical partner - a mark of established infrastructure and a reminder that the clinical team isn't exclusive to LIV Body.
One more thing worth noting: per the March 3, 2026 FDA press announcement (FDA.gov press announcement, March 3, 2026), the agency targeted companies that made claims implying sameness with FDA-approved products or that obscured the compounded nature of medications. If you're comparing platforms, the quality of their compliance disclosures is a meaningful signal. A platform that accurately represents what its medications are - and what they aren't - is a meaningfully different starting point than one that doesn't.
Buyer Takeaway: LIV Body competes on community, active lifestyle positioning, and integrated support. If that fits your goals and background, the platform is worth evaluating through the intake process. Compare compliance disclosures across platforms - not just price.
Semaglutide vs. Tirzepatide: How to Think About Which One LIV Body Discusses
LIV Body's program discusses both compounded semaglutide and compounded tirzepatide. Your provider determines which, if either, is appropriate for you based on independent clinical judgment - but it helps to go into that conversation with a basic understanding of how the two medications differ as a class.
Semaglutide is a GLP-1 receptor agonist - it activates one receptor type involved in appetite regulation and insulin secretion. It's the active ingredient in Wegovy® and Ozempic®. The STEP-1 trial data shows approximately 14.9% average body weight reduction at 68 weeks under controlled conditions for FDA-approved semaglutide - not for any compounded version. LIV Body's brand-stated starting price for compounded semaglutide is $179/month; confirm at checkout.
Tirzepatide is a dual GLP-1 and GIP receptor agonist - it activates two receptor types simultaneously. GIP (glucose-dependent insulinotropic polypeptide) is a separate incretin hormone that works in complementary ways to GLP-1. The SURMOUNT-1 trial showed approximately 20.9% average body weight reduction at 72 weeks under controlled conditions with the highest dose of FDA-approved tirzepatide. LIV Body describes compounded tirzepatide as the "Advanced Option," with a brand-stated starting price of $279/month; confirm at checkout.
Neither medication is inherently "better" - the right choice depends on your health history, risk profile, medication tolerance, and your provider's clinical assessment. Some patients respond better to semaglutide; others to tirzepatide; some experience significant side effects with one but not the other. Your provider makes this determination based on independent clinical judgment.
Both are administered as weekly self-injections in LIV Body's program per brand materials. If you've never self-injected before, ask your provider about administration technique and what to expect during your initial consultation.
Buyer Takeaway: Both medications have substantial clinical evidence as a class. Tirzepatide shows larger average weight loss in trials for the brand-name version. Semaglutide has a longer established evidence history. Your provider determines which, if either, is appropriate for your specific situation - not the price point or the brand description.
Who Is LIV Body's GLP-1 Program Designed For - and Who It's Not For
LIV Body's lander answers this question partially through the eligibility screening. But it's worth being straightforward about who fits and who doesn't.
The program is designed for adults 18 and older who meet standard GLP-1 prescribing eligibility criteria - typically BMI 30 or higher, or BMI 27 or higher with at least one qualifying weight-related condition (such as hypertension, type 2 diabetes, dyslipidemia, or sleep apnea). The specific eligibility criteria are determined by your licensed provider through OpenLoop Healthcare Partners, PC, based on independent clinical review. The brand's intake form screens for eligibility before you reach the provider review stage.
LIV Body's brand positioning is particularly targeted toward people who are already physically active and want to address a metabolic component that's resisting their efforts. The "Muscle Guard" strategy and supplement integration are designed to support performance and body composition during weight loss - brand-positioned elements that matter more to active people than to those who aren't training.
The program is not designed for people who are looking for a passive weight loss solution without lifestyle engagement. GLP-1 medications are more effective when combined with dietary changes and physical activity - and LIV Body's program design reflects this. The brand's framing is about making the biological component of weight management more workable alongside sustained effort, not about replacing that effort.
The program is not appropriate for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. It isn't appropriate for people who are pregnant or planning to become pregnant. It isn't right for anyone seeking FDA-approved finished products rather than compounded alternatives. And it isn't right for anyone who can't engage actively with their licensed provider throughout the program.
Buyer Takeaway: LIV Body's GLP-1 program is designed for medically eligible adults - particularly those with an active lifestyle who are hitting a metabolic wall their fitness efforts alone can't address. If you don't meet eligibility criteria or have contraindications, your provider will screen you out at intake. That's the system working correctly.
What Side Effects Does GLP-1 Medication Cause - What LIV Body's Program Addresses
GLP-1 medications have a well-documented side effect profile that you should understand before enrolling in any program offering them. This section won't soften it - you deserve an honest picture.
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These tend to be most pronounced during dose escalation - the period when your dose is increasing toward the therapeutic maintenance level. Many patients experience some degree of nausea in the first several weeks of treatment. Side effects may be manageable for some patients under provider guidance, but some patients experience significant or serious symptoms and should contact a healthcare professional promptly if that happens.
LIV Body's Care Coach program is positioned in part around helping patients manage side effects. Your provider and Care Coach can advise on dietary strategies (smaller, more frequent meals; avoiding high-fat foods during escalation), hydration, and pacing adjustments that may help reduce gastrointestinal discomfort.
Muscle loss is a meaningful risk during rapid weight loss, particularly at higher doses. This is the clinical reality behind LIV Body's "Muscle Guard" nutritional strategy positioning - the brand describes it as designed to support lean-mass maintenance. Adequate protein intake and resistance training are the standard clinical recommendations for preserving lean mass during GLP-1 treatment. Discuss specific targets with your licensed provider.
Rare but serious side effects include pancreatitis, gallbladder disease, and the theoretical risk of thyroid C-cell tumors seen in animal studies (not confirmed in humans at therapeutic doses). Your provider will discuss these with you and screen your history for risk factors during intake.
Additionally, the FDA has raised concerns specifically about compounded GLP-1 products: dosing errors, improper storage during shipping, fraudulent products, adverse event reports, and the use of semaglutide salt forms that should not be used for compounding have all been documented. These are documented category risks that patients should discuss with their licensed provider and dispensing pharmacy before use.
Buyer Takeaway: GLP-1 side effects are real, common during dose escalation, and worth discussing with your provider before your first dose. Contact your provider promptly if you experience severe or persistent effects. For a medical emergency, call 911 or go to the nearest emergency room - telehealth providers do not address emergencies.
Shipping, Storage, Medication Label, and Pharmacy Verification
Most GLP-1 advertorial articles skip this section entirely. Don't skip it.
LIV Body states that approved medication is shipped overnight from one of its listed pharmacy providers in discreet, temperature-controlled, unmarked packaging with free expedited shipping. Confirm current shipping terms before enrollment.
Compounded GLP-1 medications require proper cold-chain handling during shipping and storage. The FDA has specifically flagged improper storage during shipping as a concern involving compounded GLP-1 products. When your medication arrives, check the packaging integrity, confirm that the medication was stored and transported correctly per the pharmacy's instructions, review the medication label for your name, prescribed dose, dosing instructions, and dispensing pharmacy information, and confirm that what you received matches what your provider prescribed.
LIV Body's published materials list four pharmacy providers. This publication has not independently audited those pharmacies' current operations, quality controls, or fulfillment practices. Ask your provider and dispensing pharmacy directly about their cold-chain standards, quality testing, and what to do if your medication appears damaged or improperly stored on arrival.
Buyer Takeaway: Medication verification and storage confirmation are steps you should take personally before your first injection. Your dispensing pharmacy and licensed provider are your primary contacts for medication-specific questions - not the platform.
LIV Body's Data Privacy and HIPAA Framework
When you enroll in LIV Body's GLP-1 program, you're sharing significant personal health information: your medical history, current medications, weight, BMI, and other sensitive data. Understanding how that information is handled is a non-negotiable part of your evaluation.
Per LIV Body's published Terms of Use, LIV Body is not itself a "Covered Entity" under HIPAA - it functions as a technology platform rather than a healthcare provider. However, the Terms state that LIV Body may function as a "business associate" of the medical groups, pharmacies, and labs it works with, which subjects it to certain HIPAA provisions in that role. Your health information is shared with OpenLoop Healthcare Partners, PC and its affiliated providers, with the pharmacy providers that fill your prescription, and potentially with diagnostic labs as part of the care coordination process.
The OpenLoop Healthcare Partners, PC telehealth consent form contains detailed disclosures about how your protected health information is used, including provisions for AI technology use in consultations, ambient listening, session recording, and disclosure to third parties. Read these disclosures in full before you click "I agree." You have the right to ask your provider what data is collected, how long it's retained, and how it's protected. The consent form provides a specific privacy contact: [email protected].
For California residents: the Open Payments database disclosure and state-specific privacy rights are disclosed in the telehealth consent form. California residents have specific rights under state privacy law that may exceed federal HIPAA protections.
Buyer Takeaway: Your health data flows through LIV Body's platform to OpenLoop Healthcare Partners, PC and to the pharmacy providers. Review the telehealth consent form and privacy policy in full before enrolling.
The LIV Body Subscription, Cancellation, and Refund Structure
LIV Body's GLP-1 program is a monthly subscription, and the Terms of Use state that fees are generally non-refundable due to the nature of the services. Know that before you enroll.
Per the published Terms: the program is billed monthly, your payment method is charged automatically at the billing cycle, and you can cancel at any time by emailing [email protected] or contacting your provider directly. After cancellation, you retain access through the end of your current billing period.
Online subscriptions and automatic renewals are subject to federal and state consumer-protection requirements, including clear disclosure of recurring charges, affirmative consent, and truthful cancellation terms. Some states impose additional automatic-renewal and cancellation requirements. Readers should review the current checkout flow, renewal terms, cancellation method, and refund policy before submitting payment. State-specific automatic-renewal rules may apply.
California Business and Professions Code Section 17600 et seq. imposes specific automatic-renewal disclosure requirements for California consumers. ROSCA (the Restore Online Shoppers' Confidence Act) requires clear cancellation procedures for online subscription programs. Verify that LIV Body's current program terms satisfy these requirements before enrolling.
Buyer Takeaway: Save the cancellation email - [email protected] - before your first billing date. Read the current Terms before you submit payment.
Frequently Asked Questions About LIV Body's GLP-1 Program
What is LIV Body's GLP-1 program?
LIV Body is a telehealth platform that connects patients to OpenLoop Healthcare Partners, PC, an independent licensed medical group whose providers review your health profile and, if clinically eligible, may prescribe compounded semaglutide or compounded tirzepatide for weight management. The program is designed around an active lifestyle model, with support elements including a Care Coach and a "Muscle Guard" nutritional strategy. LIV Body itself does not prescribe - licensed providers through OpenLoop Healthcare Partners, PC make all clinical decisions independently. Approval is not guaranteed.
What can buyers verify about LIV Body GLP-1 before enrolling?
Buyers can verify several published program details: LIV Body identifies itself as the platform, OpenLoop Healthcare Partners, PC is identified in the telehealth consent materials as the clinical provider group, and LIV Body's published materials list multiple pharmacy providers involved in fulfillment. The brand publishes contact information, pricing references, and disclosures explaining that compounded GLP-1 medications are not FDA-approved finished drug products. This article does not independently audit medical licensure, pharmacy operations, fulfillment practices, patient outcomes, or legal compliance. Verify current terms, clinical eligibility, medication details, and provider guidance directly before enrolling.
How much does LIV Body GLP-1 cost per month?
Per the brand's published information as of June 2026: compounded semaglutide starts at $179/month and compounded tirzepatide starts at $279/month per the lander. The program FAQ states the LIV Body GLP-1 program starts at $249/month including medical consultation, ongoing provider support, and customized treatment plan. Because medication type, dosage, and program terms may vary, verify the exact current price, renewal terms, and included services at checkout before submitting payment. Prices are subject to change.
Are the compounded medications LIV Body discusses FDA-approved?
No. Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products. They may be prepared using the same active pharmaceutical ingredients as certain FDA-approved brand-name GLP-1 medications, but they are not the same products and are not FDA-approved. FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Per a March 3, 2026 FDA press announcement (FDA.gov press announcement, March 3, 2026), the FDA issued warning letters to 30 telehealth companies for making claims that implied sameness with FDA-approved products. This is accurately disclosed on LIV Body's own website and in the telehealth consent form. Your licensed provider can explain what this distinction means for your individual situation.
Who prescribes the medication in LIV Body's program?
Licensed providers employed by or contracted with OpenLoop Healthcare Partners, PC make all prescribing decisions. LIV Body itself does not prescribe. The provider reviews your intake, determines clinical eligibility, and writes a prescription only if medically appropriate based on independent clinical judgment. Your provider may be a physician, nurse practitioner, or physician assistant licensed in your state. Approval is not guaranteed regardless of your intake responses.
How does LIV Body ship medication?
Per the brand's published materials, approved medication is shipped from one of the listed pharmacy providers to your door in discreet, unmarked, temperature-controlled packaging. LIV Body states free expedited shipping is included - confirm current shipping terms before enrollment. When your medication arrives, verify the packaging integrity, medication label, dosing instructions, and storage requirements before use.
Can you cancel LIV Body GLP-1 at any time?
Yes. You can cancel by emailing [email protected] with your name and account email, or by contacting your provider directly. You retain access through the end of your billing period. Fees already paid are generally non-refundable under the Terms of Use. Save the cancellation contact before your first payment and read the current Terms at livbody.com before enrolling.
Does LIV Body accept insurance?
No, per the brand's positioning. The program is cash-pay. HSA and FSA funds may be applicable - verify with your plan administrator before assuming coverage.
Who is Paige Hathaway and what is her role in LIV Body's program?
Paige Hathaway is a fitness personality and the public brand founder associated with LIV Body. The fitness-community framing she brings to the brand comes from her background watching motivated, active people still hit metabolic walls that training alone couldn't resolve. Her role is brand, community, and fitness-positioning related. Paige Hathaway does not prescribe medication, does not determine clinical eligibility, and does not supervise patient care. Clinical prescribing is handled separately by licensed providers through OpenLoop Healthcare Partners, PC.
What states does LIV Body serve?
Per the brand, all 50 states plus Washington, D.C. The Terms of Use note that some services may not be available in all states and that coverage is subject to change. Verify availability in your specific state before beginning the intake process.
How does LIV Body's Care Coach program work?
Per the brand's lander, a dedicated Care Coach is included in the program to help patients manage side effects and support program adherence. LIV Body references a "lose up to 6% more weight" figure in connection with Care Coach enrollment - this publication has not independently verified the methodology, sample size, or comparison group behind that figure. Individual results vary and coaching should not be treated as a guarantee of additional weight loss. The Care Coach operates as a support layer alongside the licensed provider, not as a replacement for clinical care.
What is "Muscle Guard" and how does it work?
LIV Body describes "Muscle Guard" as a nutritional strategy designed to support lean-mass maintenance during weight loss. Muscle loss during rapid weight loss - particularly at higher GLP-1 doses - is a documented clinical concern. The brand pairs this strategy with its supplement line for program members. This publication has not independently verified body-composition outcomes from the protocol. For clinical guidance on lean mass preservation during GLP-1 treatment, discuss protein intake targets and resistance training protocols with your licensed provider.
What happens if I don't qualify for a GLP-1 prescription?
If LIV Body's intake screening determines you don't meet initial eligibility criteria, you'll be notified and won't proceed to provider review. If you pass intake screening but the licensed provider determines GLP-1 medication isn't clinically appropriate after reviewing your profile, you'll receive notification and guidance about alternative care options. Per OpenLoop's published consent form, the provider will inform you of next steps. You won't receive medication without passing both the automated screening and the provider's independent clinical review.
How does LIV Body compare to Wegovy or Ozempic?
LIV Body doesn't offer Wegovy® or Ozempic® - those are FDA-approved brand-name medications available through traditional pharmacy and insurance channels. LIV Body's program involves compounded semaglutide and compounded tirzepatide. These are not the same products as Wegovy® or Ozempic®. They may be prepared using the same active pharmaceutical ingredients, but they are distinct compounded preparations that are not FDA-approved. The FDA issued warning letters in March 2026 (FDA.gov press announcement, March 3, 2026) specifically targeting companies that implied otherwise. The cost difference between brand-name and compounded GLP-1 programs is significant; your licensed provider can discuss which approach makes more sense for your clinical profile and insurance situation.
Is tirzepatide or semaglutide more effective for weight loss?
Published clinical trial data generally shows higher average weight loss with brand-name tirzepatide than with brand-name semaglutide in controlled conditions - approximately 20.9% body weight reduction with tirzepatide in the SURMOUNT-1 trial versus approximately 14.9% with semaglutide in the STEP-1 trial. These reflect brand-name medications in clinical trials, not guaranteed outcomes from any compounded version in a real-world program. Individual response varies substantially, and clinical decision-making should be based on your health profile, medical history, and provider assessment.
What are the most common side effects of GLP-1 medications?
The most commonly reported side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These are most common during dose escalation and may decrease as the body adjusts. Serious but less common side effects include pancreatitis and gallbladder disease. Your licensed provider will discuss your personal risk profile during the intake process. If you experience severe or persistent side effects, contact your provider promptly. For a medical emergency, call 911 or go to the nearest emergency room.
How long does it take to see results with LIV Body's program?
LIV Body's lander states patients typically see results of 1-2 pounds per week weight loss after 4 weeks involving healthy diet and exercise changes - this is a brand-stated figure. Published GLP-1 trial data shows most weight loss occurs over a multi-month period as doses escalate to therapeutic levels. Meaningful results in clinical studies generally become apparent over 12 to 24 or more weeks. Individual results depend on your starting weight, adherence to the program, lifestyle changes, dose escalation pace, and physiological response.
What are semaglutide salt forms and why does the FDA flag them?
The FDA has specifically raised concerns about compounded products that use semaglutide salt forms - such as semaglutide sodium and semaglutide acetate - rather than the base form of semaglutide. According to the FDA, these salt forms should not be used for compounding because they are not the same as semaglutide base and have not been shown to be safe or effective. When evaluating any compounded GLP-1 program, ask your provider and dispensing pharmacy specifically what form of the active ingredient is being used in your prescription.
What has the FDA said about misleading marketing claims for compounded GLP-1 programs?
The FDA has warned that compounded GLP-1 drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing. The FDA has also raised concerns about compounded GLP-1 products, including dosing errors, improper storage during shipping, fraudulent products, adverse event reports, and the use of semaglutide salt forms that should not be used for compounding. Beyond those standing concerns, in a press announcement dated March 3, 2026 (FDA.gov press announcement, March 3, 2026), the FDA issued warning letters to 30 telehealth companies for making false or misleading claims about compounded GLP-1 products. The primary violations identified included making claims that implied sameness with FDA-approved products and advertising drug products under a telehealth brand's trademark without clearly disclosing the compounded nature of the medication. FDA Commissioner Marty Makary stated that the agency was paying close attention to misleading claims "across all media platforms." For consumers, the most important compliance signal to look for in any compounded GLP-1 program is whether the company accurately describes what its medications are and are not. This article is based entirely on LIV Body's own published disclosures, which accurately state that compounded medications are not FDA-approved.
LIV Body GLP-1 Buyer Verification Checklist - 15 Things to Confirm Before You Enroll
Verify the licensed medical group name: Confirm that OpenLoop Healthcare Partners, PC (or its state-specific affiliate) is the entity providing clinical services in your state before signing the telehealth consent form.
Confirm your eligibility criteria: Understand the BMI and condition thresholds that determine GLP-1 eligibility so you're not surprised by the intake outcome.
Read the telehealth consent form in full: OpenLoop Healthcare Partners, PC's consent form discloses AI use, recording, data sharing, and your rights as a patient. Don't click "I agree" without reading it.
Confirm current pricing at checkout: Published starting prices may differ from current checkout prices for your medication type and dose. Confirm the total before entering payment information.
Save the cancellation email address: [email protected] - document it before your first billing date.
Understand the non-refundable fee policy: Healthcare service fees are generally non-refundable per the Terms of Use. Read the current Terms before submitting payment.
Verify state availability: Confirm the program services are available in your specific state before beginning the intake process.
Ask your provider about your specific dispensing pharmacy: Ask which pharmacy will fulfill your prescription and verify current operations before your first shipment.
Verify the medication label and dosing instructions before your first injection: Check that what arrived matches your prescription - verify the form of the active ingredient, dosing schedule, and storage requirements with your dispensing pharmacy.
Discuss contraindications with your provider: Personal or family history of medullary thyroid carcinoma, MEN2, pancreatitis, gallbladder disease, or other relevant conditions should be disclosed during intake.
Understand the compounded vs. FDA-approved distinction: Know what you're receiving before you inject it. Ask your provider about the active ingredient form in your specific prescription.
Confirm HSA/FSA applicability: The program doesn't accept insurance. Before assuming HSA or FSA covers it, contact your plan administrator directly.
Review the Privacy Policy and data use disclosures: Understand where your health information goes before you share it on the intake form.
Ask about dose escalation timeline and side effect management: Going into treatment knowing what the first 4-8 weeks of dose escalation may feel like helps you stay in communication with your provider through the adjustment period.
Set a 30-day check-in reminder with your provider: Ongoing provider communication is part of the program's value. Use it proactively rather than waiting for problems to escalate.
Ask which compounding pathway your pharmacy uses: Before your first fill, confirm whether your dispensing pharmacy operates under 503A patient-specific compounding or 503B outsourcing. The 503A pathway is currently intact; the 503B pathway is under active regulatory review as of June 2026.
Confirm no FDA warning letters or enforcement actions: Ask the platform directly whether any of its named pharmacy providers have received FDA warning letters, inspection notices, or enforcement correspondence. This publication has not independently audited current compliance status of LIV Body's named pharmacies.
Ask how the platform is positioned for the 503B proposal: The FDA's April 30, 2026 proposal to remove semaglutide and tirzepatide from the 503B bulks list has a comment period closing June 29, 2026. Ask LIV Body how its pharmacy network is structured relative to this proposal and what its continuity plan is if the proposal is finalized.
Check current LIV Body GLP-1 eligibility and program details (official LIV Body page)
Additional Frequently Asked Questions
Can I use LIV Body if I've never tried GLP-1 medication before?
Yes - the program is designed for first-time GLP-1 patients as well as those switching from other platforms or programs, based on provider eligibility determination. Your provider will determine the appropriate starting dose and escalation schedule for your specific situation. Dose escalation protocols for first-time patients are designed to minimize side effects during the adjustment period.
What does "Food Noise" actually mean in clinical terms?
"Food Noise" is colloquial language, not a formal medical term. In clinical literature, the underlying phenomenon relates to how appetite-regulating hormones - particularly GLP-1, ghrelin, and leptin - interact with reward and satiety pathways in the brain. GLP-1 receptor agonists activate receptors in the hypothalamus and brainstem that regulate appetite signals. Some clinical reports and patient accounts describe reductions in food-related preoccupation on GLP-1 therapy. This is not a guaranteed effect, it doesn't work the same way for every patient, and it can't be promised by any program.
Does LIV Body's program require exercise?
Exercise isn't a stated enrollment requirement, but LIV Body's brand positioning is specifically designed for people who are active or who want to incorporate physical activity as part of their weight management approach. GLP-1 clinical guidance broadly recommends combining medication with lifestyle changes including physical activity to support results and minimize muscle loss. LIV Body's "Muscle Guard" strategy and Care Coach program are brand-positioned around active engagement, not passive treatment.
How does LIV Body handle medication shortages?
The brand's lander states it partners with multiple pharmacy providers and that its team meets regularly with pharmacies to discuss product shortages and shipping delays. Using a network of listed pharmacy providers may offer some flexibility in the event one pharmacy faces supply constraints. Specific shortage policies - substitution procedures, communication timelines, options if medication is unavailable - should be confirmed directly with the brand or your provider at enrollment.
What should I know about compounded GLP-1 safety concerns the FDA has flagged?
The FDA has documented several concerns specifically involving compounded GLP-1 products: dosing errors (including doses far exceeding the FDA-approved label), improper storage during shipping affecting medication integrity, reports of fraudulent or counterfeit compounded products, adverse event reports associated with compounded GLP-1 use, and the use of semaglutide salt forms (such as semaglutide sodium or semaglutide acetate) that should not be used for compounding. Per a March 3, 2026 FDA press announcement (FDA.gov press announcement, March 3, 2026), the FDA issued warning letters to 30 telehealth companies for making false or misleading claims about compounded GLP-1 products, including claims that implied sameness with FDA-approved medications. These are documented category risks that patients should discuss with their licensed provider and dispensing pharmacy before use.
Is compounded semaglutide still available in 2026?
Yes, but the legal pathway has narrowed significantly from 2022-2025. The FDA declared the semaglutide shortage resolved on February 21, 2025, and the tirzepatide shortage resolved in late 2024. Both resolutions ended the broad shortage-based legal pathway that enabled large-scale 503B outsourcing facility compounding. As of June 2026, the 503A patient-specific compounding pathway - under which a state-licensed pharmacy fills an individual prescription with documented clinical justification - remains intact. On April 30, 2026, the FDA proposed removing both drugs from the 503B bulks list entirely, with a public comment period open through June 29, 2026. That proposal is not yet finalized. Before enrolling in any compounded GLP-1 program, confirm with the platform and your provider which legal pathway your dispensing pharmacy operates under and its current operational status.
What is the difference between 503A and 503B compounding for GLP-1 medications?
Section 503A of the Federal Food, Drug, and Cosmetic Act covers state-licensed pharmacies that compound medications for individual patients based on valid, patient-specific prescriptions. This pathway does not depend on the FDA drug shortage list in the same way as 503B. Section 503B covers FDA-registered outsourcing facilities producing larger volumes - but only when specific conditions are met, including appearance on the FDA shortage list or the 503B bulks list. With semaglutide and tirzepatide removed from the shortage list in 2024-2025, and a formal April 30, 2026 FDA proposal to remove both from the 503B bulks list, the 503B pathway is under active regulatory pressure. The 503A pathway remains the primary current legal route for individual patient-specific compounded GLP-1 prescriptions, subject to clinical documentation requirements.
What does the FDA's April 30, 2026 compounding proposal mean for GLP-1 access?
On April 30, 2026, the FDA formally proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulks list (Federal Register docket 2026-08552), citing no current clinical need for outsourcing facilities to compound these drugs from bulk drug substances. The public comment period runs through June 29, 2026. If finalized after the comment period, the proposal would close the 503B large-scale compounding pathway for these medications with no remaining legal route for outsourcing facilities. The 503A patient-specific compounding pathway would remain as the narrower, intact legal route. This is a proposed rule, not yet finalized. Patients evaluating any compounded GLP-1 program should ask their platform and provider directly how this proposal affects their specific prescription and dispensing pharmacy.
Should the current regulatory environment change my decision about LIV Body's GLP-1 program?
The regulatory environment does not eliminate compounded GLP-1 access in June 2026 - it narrows it. The 503A patient-specific pathway remains legally intact. What the regulatory environment does change is the information you need to gather before committing: which pharmacy pathway your dispensing pharmacy uses, whether that pharmacy has received any FDA correspondence, and how the platform is positioned for continued fulfillment. These are questions worth asking before any monthly subscription health commitment. They're not reasons to avoid the program - they're the standard of due diligence that this regulatory moment requires from any informed buyer.
Are there FDA-approved alternatives to compounded GLP-1 medications in 2026?
Yes. FDA-approved options include Wegovy® (semaglutide, chronic weight management), Ozempic® (semaglutide, type 2 diabetes), Zepbound® (tirzepatide, chronic weight management), and Mounjaro® (tirzepatide, type 2 diabetes). An oral formulation of Wegovy® received FDA approval in late 2025. Eli Lilly offers Zepbound® directly through LillyDirect at brand-stated prices of $299-$449 per month. A Medicare GLP-1 Bridge program covering Wegovy® and Zepbound® under Part D at a reported $50/month copay is expected to begin July 2026. The primary tradeoff between FDA-approved brand-name options and compounded alternatives is cost versus regulatory status. Your licensed provider is the right person to discuss which option is appropriate for your clinical situation and financial circumstances.
Quick Answer Blocks
What can buyers verify about LIV Body GLP-1 before enrolling?
LIV Body's platform identity, its clinical partner (OpenLoop Healthcare Partners, PC), its listed pharmacy providers, its published pricing, and its FDA-status disclosures are all publicly verifiable from the brand's own website and the OpenLoop telehealth consent form. This article does not independently audit medical licensure, pharmacy operations, or patient outcomes. Verify current terms, pricing, and clinical eligibility directly with LIV Body and your licensed provider before enrolling.
What is compounded semaglutide and what do I need to know about it?
Compounded semaglutide may be prepared using the same active pharmaceutical ingredient as FDA-approved Wegovy® and Ozempic®, but it is not the same finished product and is not FDA-approved. FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Per a March 3, 2026 FDA press announcement (FDA.gov press announcement, March 3, 2026), the FDA issued warning letters to 30 telehealth companies specifically for making claims that implied sameness with FDA-approved products. Whether compounded semaglutide is appropriate for your specific situation is a question for your licensed provider.
How much does LIV Body's GLP-1 program cost in 2026?
LIV Body's brand-stated pricing as of June 2026 starts at $179/month for compounded semaglutide and $279/month for compounded tirzepatide, with the program overall described on the lander FAQ as starting at $249/month. Verify the exact current price, renewal terms, and included services at checkout before submitting payment - prices are subject to change. The program is a monthly subscription with cancellation available at any time per the published Terms.
Can I cancel LIV Body GLP-1 anytime?
Yes. You can cancel by emailing [email protected] with your name and account email, or by contacting your provider directly. You retain access through the end of your billing period. Fees already paid are generally non-refundable under the Terms of Use. Save the cancellation contact before your first payment and read the current Terms at livbody.com before enrolling.
Is compounded semaglutide still legal and available through telehealth in 2026?
Yes, through the 503A patient-specific compounding pathway - though the landscape has changed materially since 2023. The FDA shortage-based compounding window that enabled large-scale 503B production closed in 2025. The 503A pathway for individual patient prescriptions by state-licensed pharmacies remains intact. On April 30, 2026, the FDA proposed removing semaglutide and tirzepatide from the 503B outsourcing bulks list; the comment period closes June 29, 2026. Before enrolling in any compounded GLP-1 telehealth program, confirm with the platform which compounding pathway your dispensing pharmacy uses and verify its current operational and legal status. The category is available - but it requires more due diligence from buyers than it did in 2024.
FDA Disclaimer: Compounded medications discussed in this article are not FDA-approved finished drug products and are not reviewed by the FDA for safety, effectiveness, or quality before marketing. These statements have not been evaluated by the Food and Drug Administration. Compounded medications are not intended to diagnose, treat, cure, or prevent any disease. Prescription medication is available only after consultation with and approval by a licensed healthcare provider, if clinically appropriate. Approval is not guaranteed. This article is not medical advice.
FTC Affiliate Disclosure: This article is an advertorial and contains affiliate links. A commission may be earned on qualifying actions or purchases made through links in this content, at no additional cost to the reader. Affiliate relationships do not influence the information provided. Disclosure is provided in accordance with FTC 16 CFR Part 255.
Testimonial and Results Disclaimer: This article references the existence of brand-reported testimonials on LIV Body's website. This publication does not reproduce specific testimonial language in ways designed to imply typical results. Customer ratings and testimonials published by LIV Body are brand-reported and have not been independently audited by this publication. Individual experiences vary and may not reflect typical results. Buyers consulting third-party reviews are encouraged to evaluate them critically.
California Subscription Disclosure (CA BPC Section 17600 / ROSCA): LIV Body's GLP-1 program is offered as a monthly subscription with automatic renewal billing. You may cancel at any time by emailing [email protected] or by contacting your provider directly. Cancellation takes effect at the end of the current billing period. Fees already charged are generally non-refundable per the brand's published Terms of Use. California Business and Professions Code Section 17600 et seq. requires clearly and conspicuously disclosed auto-renewal terms before a consumer is charged. Verify all subscription terms directly on the official LIV Body website before enrolling. State-specific automatic-renewal rules may apply.
Geographic and Jurisdiction Disclosure: This article is intended for US readers. LIV Body states it serves all 50 states plus Washington, D.C., subject to change. Some services may not be available in all states. EU consumers: buyers in the European Union have consumer rights under the EU Omnibus Directive, the Distance Selling Directive, and applicable consumer protection law that may differ from US standards. Brand-stated pricing references should be verified for EU-specific pricing and applicable consumer rights.
Prop 65 Disclosure: This article covers a telehealth services program, not an ingestible supplement or consumer product manufactured for direct sale. For any supplement products offered by LIV Body as part of its supplement line (separate from the GLP-1 medical program), California consumers should verify the product label or contact LIV Body directly at [email protected].
Trademark Acknowledgment: Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. Zepbound® and Mounjaro® are registered trademarks of Eli Lilly and Company. These trademarks are used in this article for nominative reference only. LIV Body does not offer Wegovy®, Ozempic®, Zepbound®, or Mounjaro®. No affiliation, endorsement, or sponsorship by or with Novo Nordisk or Eli Lilly is implied. LIV Body is a brand of LivBody HoldCo LLC; no registered trademark symbol has been confirmed on the brand's official website as of the date of this publication.
Material Limitations of This Review. This review is based exclusively on publicly available materials, including the official LIV Body website at go.livbody.com, the brand's published Terms of Use, and the OpenLoop Healthcare Partners, PC Telehealth Consent Form last updated September 24, 2025. This publication has not received compensated product samples for testing, has not interviewed brand personnel, has not been granted access to internal product specifications beyond what is publicly published, has not conducted laboratory or clinical performance testing, and has not independently audited current licensing, fulfillment, pharmacy operations, or quality practices of the listed pharmacy providers. Claims described as "according to the brand," "brand-stated," or "per the brand's published materials" reflect what the brand has publicly stated and have not been independently substantiated by this publication. Promotional language referenced in the title or body of this article - including but not limited to phrases such as "Clinician Prescribed" and "USA Made" - originates with the LIV Body brand's own published marketing materials and is identified in this article for reader-context purposes, not as independent endorsement or performance guarantee.
Third-Party Consumer Feedback Platforms. This article references the existence of third-party consumer feedback platforms in general category terms only. This publication does not endorse, vouch for, audit, or accept responsibility for the accuracy, completeness, or fairness of customer reviews posted on any third-party platform. Buyers consulting third-party reviews are encouraged to evaluate them critically and weigh reviewer-specific context against their own situation.
Forward-Looking Statements and Article Accuracy. This article reflects information available as of June 2026 and was prepared using reasonable care to be accurate and useful at the time of publication. Product specifications, pricing, promotional offers, shipping policies, subscription terms, contact information, and customer feedback data may change after publication without notice. Statements describing expected buyer outcomes, performance expectations, or category trends are educational forward-looking observations, not guarantees. Readers should rely on the official LIV Body website as the authoritative source for current program information prior to any enrollment decision.
Reasonable Consumer Standard. This article is written for a general adult consumer audience and intends statements to be interpreted as a reasonable consumer would interpret them in context. Attribution language such as "according to the brand," "brand-stated," or "per the brand's published materials" identifies brand claims that have not been independently verified by this publication. Promotional superlatives and headline marketing phrases appearing on the brand's website - including, without limitation, "Clinician Prescribed," "USA Made," "Work with your biology, not against it," "Food Noise," "Muscle Guard," "Doctor-led plans," and "Stop Fighting Your Biology" - are explicitly identified in this article as brand-asserted marketing language and are not represented as independent third-party rankings, performance guarantees, or laboratory-verified claims by this publication.
No Affiliation With Featured Persons: This article references Paige Hathaway as the publicly disclosed founder and brand figure associated with LIV Body, as stated on the brand's own official website. This publication has no affiliation, endorsement relationship, or sponsorship arrangement with Paige Hathaway personally. Her mention reflects her publicly acknowledged role with the brand. Paige Hathaway does not prescribe medication and is not a medical provider in connection with this program.
Compounded Medication Disclosure: Compounded medications discussed in this article - including compounded semaglutide and compounded tirzepatide - are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality before marketing. Per a March 3, 2026 FDA press announcement (FDA.gov press announcement, March 3, 2026), the FDA issued warning letters to 30 telehealth companies for making false or misleading claims about compounded GLP-1 products, including claims implying sameness with FDA-approved medications. Patients should only use prescription medication under licensed-provider supervision and should verify the dispensing pharmacy, medication label, dosing instructions, storage requirements, and administration instructions before use. The decision to use compounded medications is guided by the licensed provider's medical judgment, informed by a telehealth consultation and your medical history.
Contact Information: LIV Body - [email protected] | (260)833-7235 | 317 6th Avenue, Suite 400, Des Moines, Iowa 50309. OpenLoop Healthcare Partners, PC privacy contact: [email protected] | 317 6th Ave. Ste. 400, Des Moines, IA 50309.
Review current LIV Body GLP-1 program details (official LIV Body page)
SOURCE: LIV Body